期刊文献+

高分辨率熔解曲线检测背景下结核分枝杆菌链霉素和乙胺丁醇耐药模式分析

Distribution characteristics of Mycobacterium tuberculosis and streptomycin and ethambutol resistance patterns by high-resolution melt analysis
下载PDF
导出
摘要 目的研究洛阳市和县区结核分枝杆菌链霉素与乙胺丁醇耐药模式,指导临床用药,补充当地耐药结核的流行病学数据。方法该研究共纳入2941例高分辨率熔解曲线(HRM)的阳性结果,评估与链霉素和乙胺丁醇耐药相关的危险因素。结果在被纳入的2941例HRM阳性病例中,18.4%对链霉素耐药,8.0%对乙胺丁醇耐药,男性对链霉素和乙胺丁醇耐药率均高于女性(19.0%vs 16.9%,P=0.129;8.0%vs 7.9%,P=0.987),城市群体高于乡村(21.3%vs 16.6%,P=0.002;9.8%vs 6.9%,P=0.004),复诊群体远高于初诊患者(25.8%vs 17.3%,P<0.001;12.1%vs 7.4%,P=0.002),年龄<51岁群体链霉素耐药率高于年龄>50岁的群体(21.1%vs 16.1%,P<0.001)。按年龄分层,链霉素及乙胺丁醇最高耐药率,男性分别出现在31~35岁和56~60岁,而女性则分别出现在21~25岁及56~60岁。多变量模型中,在调整了涂片结果和年份检测后,既往治疗史、年龄<51岁、城镇地区与链霉素和乙胺丁醇耐药性呈正相关。结论该地区男性、既往治疗史、年龄<51岁和城镇居住群体是链霉素与乙胺丁醇耐药结核的重点监测目标。 Objective To study the resistance pattern of streptomycin and ethambutol in Mycobacterium tuberculosis in Luoyang area,guide clinical medication and supplement epidemiological data on local drug-resistant tuberculosis.Methods The positive results of high-resolution melting curve(HRM)in 2941 cases in Luoyang area were analyzed to assess the risk factors associated with streptomycin and ethambutol resistance.Results Of the 2941 HRM-positive patients,18.4% were resistant to streptomycin and 8.0% were ethambutol.Both streptomycin and ethambutol and resistance rates were higher in men than those in women(19.0%vs 16.9%,P=0.129;8.0%us 7.9%,P=0.987).The resistance rates to streptomycin and ethambutol were higher in urban than those in rural areas(21.3%vs 16.6%,P=0.002;9.8%vs 6.9%,P=0.004).The resistance rate was much higher in previously treated patients than those newly diagnosed for MTB infection(25.8%s 17.3%,P<0.001;12.1%vs 7.4%,P=0.002).The resistance rates to streptomycin were higher in the<51 years than those in the>50 years group(21.1%us 16.1%,P<0.001).According to age,the highest resistance rates to streptomycin and ethambutol occurred in the age range of 31-35 years and 56-60 years in men,respectively,while in the age range of 21-25 years and 56-60 years in women,respectively.In multivariate models,prior treatment history,age less than 51 years,and urban area were positively associated with streptomycin and ethambutol resistance after adjusting for smear results and year testing.Conclusion Men,prior treatment history,age less than 51 years,and urban residents are key monitoring targets for streptomycin and ethambutol resistant tuberculosis.
作者 郭腾飞 王珍珍 侯义 赵战勤 祖向阳 江涛 薛云 Guo Tengfei;Wang Zhenzhen;Hou Yi;Zhao Zhanqin;Zu Xiangyang;Jiang Tao;Xue Yun(College of Clinical Medicine,Henan University of Science and Technology,Dept of Clinical Laboratory,The First Affiliated Hospital of Henan University of Science and Technology,Luoyang 471000;College of Medical Technology and Engineering,Henan University of Science and Technology,Luoyang 471000;Luoyang Center for Disease Control and Prevention,Luoyang 471000;Animal Science and Technology,Henan University of Science and Technology,Luoyang 471000)
出处 《安徽医科大学学报》 CAS 北大核心 2023年第7期1227-1232,共6页 Acta Universitatis Medicinalis Anhui
基金 国家自然科学基金(编号:32072899) 河南科技发展计划项目(编号:212102310741) 河南省科技攻关计划项目(编号:LHGJ20200589)。
关键词 结核分枝杆菌 耐药模式 分子耐药 链霉素 乙胺丁醇 Mycobacterium tuberculosis resistance patterns molecular resistance streptomycin ethambutol
  • 相关文献

参考文献3

二级参考文献18

  • 1张国龙,杜长梅,苍泽卓也,池田雄史,王伟,石瑞如.中日合作对河南省结核菌二线药物耐药监测研究[J].医药论坛杂志,2005,26(19):14-16. 被引量:15
  • 2社区获得性肺炎诊断和治疗指南[J].中华结核和呼吸杂志,2006,29(10):651-655. 被引量:3041
  • 3中华人民共和国卫生部.全国结核病耐药性基线调查报告(2007—2008年)[R].北京:人民卫生出版社.2010.
  • 4中国防痨协会基础专业委员会.结核病诊断实验室检验规程[M].北京:中国教育出版社,2006.13-16.
  • 5Word Health Organization. Multidrug and extensively drug-re-sistant TB(M/XDR-TB) : 2010 global report on surveillance andresponse[R]. Geneva: WHO. 2010 : 5-10.
  • 6ShahNS, Wright A,Bai GH. Worldwide emergence of exten-sively drug-resistant tuberculosis[J]. Emerg Infect Dis, 2007,13(3): 380-387. DOI: 10. 3201/eidl303. 061400.
  • 7WorldHealth Organization. Anti-tuberculosis Drug Resistance inthe World: Fourth Global Report: the World Health Organiza-tion/International Union against Tuberculosis and Lung Disease(WHO/UNION) Global Project on Anti-Tuberculosis Drug Re-sistance Surveillance, 2002-2007 [ R]. Geneva: World HealthOrganization, 2008.
  • 8HelbingP,Altpeter E, Raeber PA, et ai. Surveillance of antitu-berculosis drug resistance in Switzerland 1995-1997: the centrallink[J]. Eur Respir J, 2000, 16: 200-202.
  • 9JeonCY, Hwang SH, Min JH,et al. Extensively drug-resist-ant tuberculosis in South Korea: risk factors and treatment out-comes among patients at a tertiary referral hospital[J]. Clin In-fect Dis, 2008,46: 42-49. DOI: 10. 1086/524017.
  • 10ToungoussovaOS, Mariandyshev AO, Bjune G, et al. Resist-ance of multidrug resistant strains oiMycobacterium tuberculosisfrom the Archangel oblast, Russia, to second-line anti-tubercu-losis drugs[J]. Eur J Clin Micmbiol Infect Dis, 2005 , 24: 202-206. DOI: 10. 1007/sl0096-005-1284-z.

共引文献88

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部